ATNFW | CannBioRx Life Sciences Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0076 - 0.0100
52 Week Range	0.0076 - 0.0100
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,106
Average Volume	N/A
Shares Outstanding	450,755,800
Market Cap	4,071,037
Sector	Healthcare
Industry	Medical - Pharmaceuticals
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	ATNFW

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

ATNFW's peers: ARKOW, IMTXW, ADVWW, BCTXW, CURIW, GOVXW, RVPHW, ARTLW, ATNF, ADILW, ENTXW, CLNNW, LIXTW

*Chart delayed

Analyzing fundamentals for ATNFW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see ATNFW Fundamentals page.

Watching at ATNFW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ATNFW Technicals page.